Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Feverish illness in children: assessment and initial management in children younger than 5 years.

BIBLIOGRAPHIC SOURCE(S)

  • National Collaborating Centre for Women's and Children's Health. Feverish illness in children: assessment and initial management in children younger than 5 years. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 May. 142 p. (Clinical guideline; no. 47). [289 references]

GUIDELINE STATUS

This is the current release of the guideline.

Clinical guidelines commissioned by National Institute for Health and Clinical Excellence (NICE) are published with a review date 4 years from date of publication. Reviewing may begin earlier than 4 years if significant evidence that affects guide­line recommendations is identified sooner. The updated guideline will be available within 2 years of the start of the review process.

** REGULATORY ALERT **

FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse (NGC): This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

  • April 14, 2009 - Rocephin (ceftriaxone sodium): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of an update to a previous alert that addresses the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. Based on the results from recent in vitro studies, FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients >28 days of age, using the precautionary recommendations noted because the risk of precipitation is low in this population. FDA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.

BRIEF SUMMARY CONTENT

 ** REGULATORY ALERT **
 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Thermometers and the Detection of Fever

The oral and rectal routes should not routinely be used to measure the body temperature of children aged 0–5 years.

In infants under the age of 4 weeks, body temperature should be measured with an electronic thermometer in the axilla.

In children aged 4 weeks to 5 years, healthcare professionals should measure body temperature by one of the following methods:

  • electronic thermometer in the axilla
  • chemical dot thermometer in the axilla
  • infrared tympanic thermometer

Healthcare professionals who routinely use disposable chemical dot thermometers should consider using an alternative type of thermometer when multiple temperature measurements are required.

Forehead chemical thermometers are unreliable and should not be used by healthcare professionals.

Reported parental perception of a fever should be considered valid and taken seriously by healthcare professionals.

Clinical Assessment of the Child with Fever

First, healthcare professionals should identify any immediately life-threatening features, including compromise of the airway, breathing or circulation, and decreased level of consciousness.

Children with feverish illness should be assessed for the presence or absence of symptoms and signs that can be used to predict the risk of serious illness using the traffic light system (see table below titled "Traffic light system for identifying risk of serious illness").

Children with the following symptoms or signs should be recognised as being in a high-risk group for serious illness:

  • unable to rouse or if roused does not stay awake
  • weak, high-pitched or continuous cry
  • pale/mottled/blue/ashen
  • reduced skin turgor
  • bile-stained vomiting
  • moderate or severe chest indrawing
  • respiratory rate greater than 60 breaths/minute
  • grunting
  • bulging fontanelle
  • appearing ill to a healthcare professional

Children with any of the following symptoms should be recognised as being in at least an intermediate-risk group for serious illness:

  • wakes only with prolonged stimulation
  • decreased activity
  • poor feeding in infants
  • not responding normally to social cues/no smile
  • dry mucous membranes
  • reduced urine output
  • a new lump larger than 2 cm
  • pallor reported by parent or carer
  • nasal flaring

Children who have all of the following features, and none of the high-or intermediate-risk features, should be recognised as being in a low-risk group for serious illness:

  • strong cry or not crying
  • content/smiles
  • stays awake
  • normal colour of skin, lips and tongue
  • normal skin and eyes
  • moist mucous membranes
  • normal response to social cues

Table. Traffic Light System for Identifying Risk of Serious Illness

Children with fever and any of the symptoms or signs in the 'red' column should be recognised as being at high risk. Similarly, children with fever and any of the symptoms or signs in the 'amber' column and none in the 'red' column should be recognised as being at intermediate risk. Children with symptoms and signs in the 'green' column and none in the 'amber' or 'red' columns are at low risk. The management of children with fever should be directed by the level of risk.

  Green – Low Risk Amber – Intermediate Risk Red – High Risk
Colour
  • Normal colour of skin, lips and tongue
  • Pallor reported by parent/carer
  • Pale/mottled/ashen/blue
Activity
  • Responds normally to social cues
  • Content/smiles
  • Stays awake or awakens quickly
  • Strong normal cry/not crying
  • Not responding normally to social cues
  • Wakes only with prolonged stimulation
  • Decreased activity
  • No smile
  • No response to social cues
  • Appears ill to a healthcare professional
  • Does not wake or if roused does not stay awake
  • Weak, high-pitched or continuous cry
Respiratory  
  • Nasal flaring
  • Tachypnoea:

    Respiratory rate (RR) >50 breaths/minute, age 6–12 months

    RR >40 breaths/minutes, age >12 months
  • Oxygen saturation ≤95% in air
  • Crackles
  • Grunting
  • Tachypnoea: RR >60 breaths/minute
  • Moderate or severe chest indrawing
Hydration
  • Normal skin and eyes
  • Moist mucous membranes
  • Dry mucous membranes
  • Poor feeding in infants
  • Capillary refill time (CRT) ≥3 seconds
  • Reduced urine output
  • Reduced skin turgor
Other
  • None of the amber or red symptoms or signs
  • Fever for ≥5 days
  • Age 0–3 months, temperature ≥38 degrees C
  • Age 3–6 months, temperature ≥39 degrees C
  • Swelling of a limb or joint
  • Non-weight bearing/not using an extremity
  • Non-blanching rash
  • Bulging fontanelle
  • Neck stiffness
  • Status epilepticus
  • Focal neurological signs
  • Focal seizures
  • A new lump >2 cm
  • Bile-stained vomiting

Healthcare professionals should measure and record temperature, heart rate, respiratory rate and capillary refill time as part of the routine assessment of a child with fever.

Healthcare professionals examining children with fever should be aware that a raised heart rate can be a sign of serious illness, particularly septic shock.

A capillary refill time of 3 seconds or longer should be recognised as an intermediate risk group marker for serious illness ('amber' sign).

Healthcare professionals should measure the blood pressure of children with fever if the heart rate or capillary refill time is abnormal and the facilities to measure blood pressure are available.

Height of body temperature alone should not be used to identify children with serious illness. However, children in the following categories should be recognised as being in a high risk group for serious illness:

  • children younger than 3 months with a temperature of 38 degrees C or higher
  • children aged 3–6 months with a temperature of 39 degrees C or higher

Duration of fever should not be used to predict the likelihood of serious illness.

Children with fever should be assessed for signs of dehydration. Healthcare professionals should look for:

  • prolonged capillary refill time
  • abnormal skin turgor
  • abnormal respiratory pattern
  • weak pulse
  • cool extremities

Healthcare professionals should look for a source of fever and check for the presence of symptoms and signs that are associated with specific diseases (see Table below titled "Summary table for symptoms and signs suggestive of specific diseases").

Meningococcal disease should be considered in any child with fever and a non-blanching rash, particularly if any of the following features are present:

  • an ill-looking child
  • lesions larger than 2 mm in diameter (purpura)
  • a capillary refill time of 3 seconds or longer
  • neck stiffness

Meningitis should be considered in a child with fever and any of the following features:

  • neck stiffness
  • bulging fontanelle
  • decreased level of consciousness
  • convulsive status epilepticus

Healthcare professionals should be aware that classical signs of meningitis (neck stiffness, bulging fontanelle, high-pitched cry) are often absent in infants with bacterial meningitis.

Herpes simplex encephalitis should be considered in children with fever and any of the following features:

  • focal neurological signs
  • focal seizures
  • decreased level of consciousness

Pneumonia should be considered in children with fever and any of the following signs:

  • tachypnoea (respiratory rate greater than 60 breaths/minute, age 0–5 months; greater than 50 breaths/minute, age 6–12 months; greater than 40 breaths /minute, age older than 12 months)
  • crackles in the chest
  • nasal flaring
  • chest indrawing
  • cyanosis
  • oxygen saturation of 95% or less when breathing air

Table. Summary Table for Symptoms and Signs Suggestive of Specific Diseases

Diagnosis to Be Considered Symptoms and Signs in Conjunction with Fever
Meningococcal disease Non-blanching rash, particularly with one or more of the following:
  • an ill-looking child
  • lesions larger than 2 mm in diameter (purpura)
  • capillary refill time of ≥3 seconds
  • neck stiffness
Meningitis Neck stiffness

Bulging fontanelle

Decreased level of consciousness

Convulsive status epilepticus
Herpes simplex encephalitis Focal neurological signs

Focal seizures

Decreased level of consciousness
Pneumonia Tachypnoea (Respiratory rate (RR) >60 breaths/minute, age 0–5 months; RR >50 breaths/minute, age 6–12 months; RR >40 breaths/minute, age >12 months)

Crackles in the chest

Nasal flaring

Chest indrawing

Cyanosis

Oxygen saturations ≤ 95%
Urinary tract infection Vomiting

Poor feeding

Lethargy

Irritability

Abdominal pain or tenderness

Urinary frequency or dysuria

Offensive urine or haematuria
Septic arthritis Swelling of a limb or joint

Not using an extremity

Non-weight bearing
Kawasaki disease Fever for more than 5 days and at least four of the following:
  • bilateral conjunctival injection
  • change in mucous membranes
  • change in the extremities
  • polymorphous rash
  • cervical lymphadenopathy

Urinary tract infection should be considered in any child younger than 3 months with fever.

Urinary tract infection should be considered in a child aged 3 months and older with fever and one or more of the following:*

  • vomiting
  • poor feeding
  • lethargy
  • irritability
  • abdominal pain or tenderness
  • urinary frequency or dysuria
  • offensive urine or haematuria

Septic arthritis/osteomyelitis should be considered in children with fever and any of the following signs:

  • swelling of a limb or joint
  • not using an extremity
  • non-weight bearing

Kawasaki disease should be considered in children with fever that has lasted longer than 5 days and who have four of the following five features:

  • bilateral conjunctival injection
  • change in mucous membranes in the upper respiratory tract (e.g., injected pharynx, dry cracked lips or strawberry tongue)
  • change in the extremities (e.g., oedema, erythema or desquamation)
  • polymorphous rash
  • cervical lymphadenopathy

Healthcare professionals should be aware that, in rare cases, incomplete/atypical Kawasaki disease may be diagnosed with fewer features.

When assessing a child with feverish illness, healthcare professionals should enquire about recent travel abroad and should consider the possibility of imported infections according to the region visited.

Management by Remote Assessment

Healthcare professionals performing a remote assessment of a child with fever should seek to identify symptoms and signs of serious illness and specific diseases as summarised in the tables above titled "Traffic Light System for Identifying Risk of Serious Illness" and "Summary Table for Symptoms and Signs Suggestive of Specific Diseases."

Children whose symptoms or combination of symptoms suggest an immediately life-threatening illness (see Chapter 4 in the original guideline document) should be referred immediately for emergency medical care by the most appropriate means of transport (usually 999 ambulance).

Children with any 'red' features but who are not considered to have an immediately life-threatening illness should be urgently assessed by a healthcare professional in a face-to-face setting within 2 hours.

Children with 'amber' but no 'red' features should be assessed by a healthcare professional in a face-to-face setting. The urgency of this assessment should be determined by the clinical judgment of the healthcare professional carrying out the remote assessment.

Children with 'green' features and none of the 'amber' or 'red' features can be managed at home with appropriate advice for parents and carers including advice on when to seek further attention from the healthcare services (see Chapter 9 in the original guideline document).

Management by the Non-Paediatric Practitioner

Management by a non-paediatric practitioner should start with a clinical assessment as described in Chapter 4 in the original guideline document. Healthcare practitioners should attempt to identify symptoms and signs of serious illness and specific diseases as summarised in the tables above titled "Traffic Light System for Identifying Risk of Serious Illness" and "Summary Table for Symptoms and Signs Suggestive of Specific Diseases."

Children whose symptoms or combination of symptoms and signs suggest an immediately life-threatening illness (see Chapter 4 in the original guideline document) should be referred immediately for emergency medical care by the most appropriate means of transport (usually 999 ambulance).

Children with any 'red' features but who are not considered to have an immediately life-threatening illness should be referred urgently to the care of a paediatric specialist.

If any 'amber' features are present and no diagnosis has been reached, healthcare professionals should provide parents or carers with a 'safety net' or refer to specialist paediatric care for further assessment. The safety net should be one or more of the following:

  • providing the parent or carer with verbal and/or written information on warning symptoms and how further health care can be accessed (see Chapter 9 in the original guideline document)
  • arranging further follow-up at a specified time and place
  • liaising with other healthcare professionals, including out-of-hours providers, to ensure direct access for the child if further assessment is required

Children with 'green' features and none of the 'amber' or 'red' features can be managed at home with appropriate advice for parents and carers, including advice on when to seek further attention from the healthcare services (see Chapter 9 in the original guideline document).

Children with symptoms and signs suggesting pneumonia who are not admitted to hospital should not routinely have a chest X-ray.

Urine should be tested on children with fever as recommended in the National Guideline Clearinghouse (NGC) summary of the National Institute for Health and Clinical Excellence (NICE) clinical guideline Urinary Tract Infection in Children.

Oral antibiotics should not be prescribed to children with fever without apparent source.

Children with suspected meningococcal disease should be given parenteral antibiotics at the earliest opportunity (either benzylpenicillin or a third-generation cephalosporin).

Management by the Paediatric Specialist

Management by the paediatric specialist should start with a clinical assessment as described in Chapter 4 in the original guideline document. The healthcare professional should attempt to identify symptoms and signs of serious illness and specific diseases as summarised in the tables above titled "Traffic Light System for Identifying Risk of Serious Illness" and "Summary Table for Symptoms and Signs Suggestive of Specific Diseases."

Infants younger than 3 months with fever should be observed and have the following vital signs measured and recorded:

  • temperature
  • heart rate
  • respiratory rate

Infants younger than 3 months with fever should have the following investigations performed:

  • full blood count
  • blood culture
  • C-reactive protein
  • urine testing for urinary tract infection (see the NGC summary of the NICE guideline, Urinary Tract Infection in Children.)
  • chest X-ray only if respiratory signs are present
  • stool culture, if diarrhoea is present

Lumbar puncture should be performed on the following children (unless contraindicated):

  • infants younger than 1 month
  • all infants aged 1–3 months who appear unwell
  • infants aged 1–3 months with white blood cell count (WBC) less than 5 x109/litre or greater than 15 x109/litre

When indicated, a lumbar puncture should be performed without delay and, whenever possible, before the administration of antibiotics.

Parenteral antibiotics should be given to:

  • infants younger than 1 month
  • all infants aged 1–3 months who appear unwell
  • infants aged 1–3 months with WBC less than 5 x109/litre or greater than 15 x109/litre

When parenteral antibiotics are indicated for infants less than 3 months of age, a third-generation cephalosporin (e.g., cefotaxime or ceftriaxone) should be given plus an antibiotic active against listeria (e.g., ampicillin or amoxicillin).

Children with fever without apparent source presenting to paediatric specialists with one or more 'red' features should have the following investigations performed:

The following investigations should also be considered in children with 'red' features, as guided by the clinical assessment:

  • lumbar puncture in children of all ages (if not contraindicated)
  • chest X-ray irrespective of body temperature and white blood cell count (WBC)
  • serum electrolytes and blood gas

Children with fever without apparent source presenting to paediatric specialists who have one or more 'amber' features should have the following investigations performed unless deemed unnecessary by an experienced paediatrician.

  • urine should be collected and tested for urinary tract infection (see Urinary Tract Infection in Children)
  • blood tests: full blood count, C-reactive protein and blood cultures
  • lumbar puncture should be considered for children younger than 1 year
  • chest X-ray in a child with a fever greater than 39 degrees C and white blood cell count (WBC) greater than 20 x109/litre
  • Children who have been referred to a paediatric specialist with fever without apparent source and who have no features of serious illness (that is, the 'green' group), should have urine tested for urinary tract infection (see Urinary Tract Infection in Children) and be assessed for symptoms and signs of pneumonia

Routine blood tests and chest X-rays should not be performed on children with fever who have no features of serious illness (that is, the 'green' group).

Febrile children with proven respiratory syncytial virus or influenza infection should be assessed for features of serious illness. Consideration should be given to urine testing for urinary tract infection (see Urinary Tract Infection in Children).

In children aged 3 months or older with fever without apparent source, a period of observation in hospital (with or without investigations) should be considered as part of an assessment to help differentiate nonserious from serious illness.

When a child has been given antipyretics:

  • healthcare professionals should not rely on a decrease or lack of decrease in temperature after 1–2 hours to differentiate between serious and non-serious illness
  • children in hospital with 'amber' or 'red' features should be reassessed after 1–2 hours

Children with fever and shock presenting to specialist paediatric care or an emergency department should be:

  • given an immediate intravenous fluid bolus of 20 ml/kg; the initial fluid should normally be 0.9% sodium chloride
  • actively monitored and given further fluid boluses as necessary

Children with fever presenting to specialist paediatric care or an emergency department should be given immediate parenteral antibiotics if they are:

  • shocked
  • unrousable
  • showing signs of meningococcal disease

Immediate parenteral antibiotics should be considered for children with fever and reduced levels of consciousness. In these cases symptoms and signs of meningitis and herpes simplex encephalitis should be sought (see table above titled "Summary Table for Symptoms and Signs Suggestive of Specific Diseases").

When parenteral antibiotics are indicated, a third-generation cephalosporin (e.g., cefotaxime or ceftriaxone) should be given, until culture results are available. For children younger than 3 months, an antibiotic active against listeria (e.g., ampicillin or amoxicillin) should also be given.

Children with fever and symptoms and signs suggestive of herpes simplex encephalitis should be given intravenous aciclovir.

Oxygen should be given to children with fever who have signs of shock or oxygen saturation (SpO2) of less than 92% when breathing air.

Treatment with oxygen should also be considered for children with an SpO2 of greater than 92%, as clinically indicated.

In a child presenting to hospital with a fever and suspected serious bacterial infection, requiring immediate treatment, antibiotics should be directed against Neisseria meningitidis, Streptococcus pneumoniae, Escherichia coli, Staphylococcus aureus and Haemophilus influenzae type b. A third-generation cephalosporin (e.g., cefotaxime or ceftriaxone) is appropriate, until culture results are available. For infants younger than 3 months, an antibiotic active against listeria (e.g., ampicillin or amoxicillin) should be added.

Healthcare professionals should refer to local treatment guidelines when rates of bacterial antibiotic resistance are significant.

In addition to the child's clinical condition, healthcare professionals should consider the following factors when deciding whether to admit a child with fever to hospital:

  • social and family circumstances
  • other illnesses that affect the child or other family members
  • parental anxiety and instinct (based on their knowledge of their child)
  • contacts with other people who have serious infectious diseases
  • recent travel abroad to tropical/subtropical areas, or areas with a high risk of endemic infectious diseases
  • when the parent or carer's concern for their child's current illness has caused them to seek healthcare advice repeatedly
  • where the family has experienced a previous serious illness or death due to feverish illness which has increased their anxiety levels
  • when a feverish illness has no obvious cause, but the child remains ill longer than expected for a self-limiting illness

If it is decided that a child does not need to be admitted to hospital, but no diagnosis has been reached, a safety net should be provided for parents and carers if any 'red' or 'amber' features are present. The safety net should be one or more of the following:

  • providing the parent or carer with verbal and/or written information on warning symptoms and how further health care can be accessed (see Chapter 9 in the original guideline document)
  • arranging further follow-up at a specified time and place
  • liaising with other healthcare professionals, including out-of-hours providers, to ensure direct access for the child if further assessment is required

Children with 'green' features and none of the 'amber' or 'red' features can be managed at home with appropriate advice for parents and carers, including advice on when to seek further attention from the healthcare services (see Chapter 9 in the original guideline document).

Children with fever who are shocked, unrousable or showing signs of meningococcal disease should be urgently reviewed by an experienced paediatrician and consideration given to referral to paediatric intensive care.

Children with suspected meningococcal disease should be given parenteral antibiotics at the earliest opportunity (either benzylpenicillin or a third-generation cephalosporin).

Children admitted to hospital with meningococcal disease should be under paediatric care, supervised by a consultant and have their need for inotropes assessed.

Antipyretic Interventions

Tepid sponging is not recommended for the treatment of fever.

Children with fever should not be underdressed or over-wrapped.

The use of antipyretic agents should be considered in children with fever who appear distressed or unwell. Antipyretic agents should not routinely be used with the sole aim of reducing body temperature in children with fever who are otherwise well. The views and wishes of parents and carers should be taken into consideration.

Either paracetamol or ibuprofen can be used to reduce temperature in children with fever.

Paracetamol and ibuprofen should not be administered at the same time to children with fever.

Paracetamol and ibuprofen should not routinely be given alternately to children with fever. However, use of the alternative drug may be considered if the child does not respond to the first agent.

Antipyretic agents do not prevent febrile convulsions and should not be used specifically for this purpose.

Advice for Home Care

Parents or carers should be advised to manage their child's temperature as described in Chapter 8 in the original guideline document.

Parents or carers looking after a feverish child at home should be advised:

  • to offer the child regular fluids (where a baby or child is breastfed the most appropriate fluid is breast milk)
  • how to detect signs of dehydration by looking for the following features:
    • sunken fontanelle
    • dry mouth
    • sunken eyes
    • absence of tears
    • poor overall appearance
  • to encourage their child to drink more fluids and consider seeking further advice if they detect signs of dehydration
  • how to identify a non-blanching rash
  • to check their child during the night
  • to keep their child away from nursery or school while the child's fever persists but to notify the school or nursery of the illness

Following contact with a healthcare professional, parents and carers who are looking after their feverish child at home should seek further advice if:

  • the child has a fit
  • the child develops a non-blanching rash
  • the parent or carer feels that the child is less well than when they previously sought advice
  • the parent or carer is more worried than when they previously sought advice
  • the fever lasts longer than 5 days
  • the parent or carer is distressed, or concerned that they are unable to look after their child

CLINICAL ALGORITHM(S)

A clinical algorithm is provided in the original guideline document: Care pathway for feverish illness in children.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of evidence supporting the recommendations is not specifically stated.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • National Collaborating Centre for Women's and Children's Health. Feverish illness in children: assessment and initial management in children younger than 5 years. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 May. 142 p. (Clinical guideline; no. 47). [289 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2007 May

GUIDELINE DEVELOPER(S)

National Collaborating Centre for Women's and Children's Health - National Government Agency [Non-U.S.]

SOURCE(S) OF FUNDING

National Institute for Health and Clinical Excellence (NICE)

GUIDELINE COMMITTEE

Guideline Development Group

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Group Members: Martin Richardson, Consultant Paediatrician, GDG Chair; Richard Bowker, Paediatric Specialist Registrar; James Cave, General Practitioner; Jean Challiner, Associate Medical Director – NHS Direct; Sharon Conroy, Paediatric Clinical Pharmacist; John Crimmins, General Practitioner; Annette Dearnum, Children's Nursing Practitioner (deputy of Jane Houghton for 2 months); Jennifer Elliott, Patient/Carer Representative; Jane Houghton, Nurse Consultant in Paediatric Ambulatory Care; Edward Purssell, Lecturer in Children's Nursing; Andrew Riordan, Consultant in Paediatric Infectious Diseases and Immunology; Peter Rudd, Consultant Paediatrician; Ben Stanhope, Consultant in Paediatric Emergency Medicine; Bridie Taylor, Patient Representative (attending meetings till February 2006)

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Andrew Riordan - Received sponsorship from an immunoglobulin manufacturer to attend a scientific meeting in Hungary; Member of North West Advisory Board on Human Papilloma Virus Vaccine (GlaxoSmithKline UK); Funding for Rotavirus epidemiology study (GSK vaccines)

Peter Rudd - Commentary on paper in Arch Dis Childhood on neonatal infection, publication date 2007 (BMJ Publications); chapter on fever in children for Forfar and O'Neill Textbook of Paediatrics, publication date 2007 (Churchill Livingstone)

Richard Bowker - Systematic review study on the use of fluid for resuscitation of children with circulation shock

James Cave - Director of Downland Services Ltd, a company that runs a dispensing National Health Service (NHS) pharmacy. Company holds agreements with pharmaceutical companies on the purchasing of drugs. Partner in The Downland Practice which dispenses medicines to a number of its patients and holds agreements with pharmaceutical companies on the purchasing of drugs.

Martin Richardson - Writing an article on childhood infections for Independent Nurse

Sharon Conroy - Member of the executive committee of the Neonatal and Paediatric Pharmacists group. This body has a number of corporate partners who are pharmaceutical manufacturers. Their financial support is used by the group to subsidise conferences, support research projects and other professional activities of the group for the educational benefit of its members and ultimately paediatric patients and their families.

Edward Pursell - Received thermoscan thermometers and covers for use in research costing 200 pounds sterling (Braun Healthcare)

Monica Lakhanpaul - Funding by the RCPCH for a project on children presenting acutely to hospital, funding to Leicester University (Well Child); 80,000 pounds sterling grant from PCT and University for Research Fellow to develop a multimedia package for implementation of EBM to undergraduates, funding to Leicester University; Research Fellow for a study of pimecrolimus effects on children, funding to Leicester University (Novartis); 201,000 pounds sterling grant for a randomised placebo-controlled trial of oral steroids versus placebo for treatment of preschool wheeze, funding to Leicester University (Asthma UK); part of a project paid by Well Child for the development of clinical guidelines for paediatric emergency care, 350,000 pounds sterling paid to Nottingham University; co-applicant of grant for 'RCT for treatment of community-acquired pneumonia: intravenous versus oral treatment', 96,000 pounds sterling; co-applicant for guideline on children with altered consciousness (Peyes Foundation)

GUIDELINE STATUS

This is the current release of the guideline.

Clinical guidelines commissioned by National Institute for Health and Clinical Excellence (NICE) are published with a review date 4 years from date of publication. Reviewing may begin earlier than 4 years if significant evidence that affects guide­line recommendations is identified sooner. The updated guideline will be available within 2 years of the start of the review process.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

Print copies: Available from the National Health Service (NHS) Response Line 0870 1555 455. ref: N1247. 11 Strand, London, WC2N 5HR.

PATIENT RESOURCES

The following is available:

Print copies: Available from the National Health Service (NHS) Response Line 0870 1555 455, ref: N1248. 11 Strand, London, WC2N 5HR.

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC STATUS

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo